Skip to main content

Table 2 Meta-regression for the association of clinicopathologic factors and the hazard ratio for disease-free and overall survival

From: Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis

Variable Studies included in analysis Standardized β coefficient P value
Overall survival  
 Median age [8, 9, 11, 1315, 2628] 0.098 0.80
 ER positive [911, 13, 15, 2327] 0.084 0.81
 HER2 positive [811, 14, 15, 2327] –0.40 0.22
 Triple negative [8, 14, 24, 27] 0.05 0.93
 Grade 1 or 2 [8, 10, 14, 15, 2325] 0.02 0.95
 Grade 3 [8, 10, 14, 15, 2325] –0.02 0.95
 Stage 0–I [9, 13, 23, 25, 27, 28] 0.68 0.14
 Stage II [9, 13, 23, 25, 27, 28] –0.30 0.56
 Stage III [9, 13, 25, 27, 28] –0.73 0.16
 Metastatic disease [811, 1315, 2428] –0.29 0.35
 Premenopausal [24, 25] 0.04 0.95
 Nodal involvement [811, 1315, 2327] –0.04 0.90
 NLR cutoff value [8, 10, 1315, 23, 24] –0.29 0.33
 Median follow-up [811, 13, 14, 23, 2528] –0.16 0.64
Disease-free survival
 Median age [8, 9, 14, 27, 29] 0.06 0.93
 ER positive [9, 10, 12, 24, 25, 27, 29] –0.77 0.04*
 HER2 positive [810, 12, 14, 24, 25, 27, 29] –0.79 0.01*
 Triple negative [8, 12, 14, 24, 27, 29] 0.63 0.18
 Grade 1 or 2 [810, 12, 14, 24, 25, 27, 29] –0.46 0.21
 Grade 3 [810, 12, 14, 24, 25, 27, 29] 0.46 0.21
 Stage 0–I [9, 25, 27, 29] 0.46 0.54
 Stage II [9, 25, 27, 29] 0.53 0.36
 Stage III [9, 25, 27, 29] –0.50 0.39
 Metastatic disease [25] –0.74 0.49
 Premenopausal [9, 12, 24, 25, 27] 0.43 0.40
 Nodal involvement [810, 12, 14, 24, 25, 27, 29] 0.25 0.52
 NLR cutoff value [810, 12, 14, 24, 25, 27, 29] –0.15 0.70
 Median follow-up [810, 12, 14, 25, 27, 29] –0.19 0.66
  1. ER estrogen receptor, NLR neutrophil-to-lymphocyte
  2. *Statistically significant at P < 0.05